ClinicalTrials.gg
Sign In

Thoracic Neoplasms clinical trials

The registry lists 115 studies for Thoracic Neoplasms across more than 10 countries. 30 are recruiting or about to start. 21 of them are mainly about Thoracic Neoplasms (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-04. Counting its 18 narrower conditions too, such as Carcinoma, Non-Small-Cell Lung: 13,109 studies, 3,378 open.

Get an email when these change. Save the Thoracic Neoplasms studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Watch these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your saved searches, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your saved searches. Stop any time.

Status

Completed
40
Recruiting
27
Status unknown
14
Terminated
14
Active, not recruiting
13
Not yet recruiting
3

Phase

Phase 2
31
Phase 1
26
Phase 3
14
Phase 4
3
Early Phase 1
1

Where

United States
52
China
23
Spain
19
France
17
Italy
15
Korea, Republic of
13

Who runs them

Revolution Medicines, Inc. (6) · AstraZeneca (6) · Fundación GECP (5) · Eli Lilly and Company (4) · Blueprint Medicines Corporation (4) · Sichuan Cancer Hospital and Research Institute (4) · Hoffmann-La Roche (3) · Syndax Pharmaceuticals (3)

What is being tested here

Drugs under test in Thoracic Neoplasms studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

DrugOpenPhase 3All
Daraxonrasib202
Elironrasib102
Olomorasib111
Osimertinib101
Tambotatug pelitecan101
Atorvastatin101
Lisinopril101
AMG 757101
Repotrectinib101
Budesonide101

Drug classes tested here Tyrosine kinase inhibitors (TKIs) 2 open · Immune checkpoint inhibitors 2 open · Antimetabolites 3

Coming up

4phase 3 studies under way
13studies finish main data collection within a year2 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 27 Thoracic Neoplasms studies recruiting now, 18 (67%) set no upper age limit and 6 (22%) stop at 75 or younger. 1 (4%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 3 (11%) take healthy volunteers.

Recruiting studies that take each age, of 27
AgeWomenMen
100 (0%)0 (0%)
1825 (93%)25 (93%)
3025 (93%)25 (93%)
4026 (96%)26 (96%)
5027 (100%)27 (100%)
6527 (100%)27 (100%)
7525 (93%)25 (93%)
8519 (70%)19 (70%)

Across all 115 studies, recruiting or not: 15% stop at 75 or younger and 2% at 65; 4% take children; 0% are for women only and 0% for men only; 9% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Thoracic Neoplasms studies take

Of 22 interventional studies with no phase under Thoracic Neoplasms, half reached primary completion within 26 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Interventional, no phase26 mo16–66 · 22 studies——

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

Studies

Recruiting first, then most recently updated. Showing 50 of 115. Browse all 115 → or search them.